With a $5 billion investment, the 3,000-employee campus leads biomanufacturing innovation while embracing AI, education and ...

Cetera Investment Advisers just upped their Amgen game, acquiring an additional 26,309 shares, now holding a hefty 226,219 ...

In the latest close session, Amgen (AMGN) was down 1.73% at $301.29. The stock's change was less than the S&P 500's daily gain of 0.02%. Meanwhile, the Dow experienced a drop of 0.14%, and the ...

This was the stock's third consecutive day of losses.

In a recently-issued Director Discretionary Denial decision, U.S. Patent and Trademark Office (USPTO) Acting Director Coke ...

Long-term shareholders have already seen significant gains from these stocks, and there's likely much more to come for ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Amgen Inc. (NASDAQ:AMGN) ranks among the best low volatility stocks to buy according to analysts. While keeping its ...

Amgen Inc. (NASDAQ:AMGN) is on the hunt for its next breakthrough drug— a common pursuit among pharmaceutical companies ...

On Nov. 26, 2019, ChemoCentryx issued a press release announcing that the Advocate trial met both of its primary endpoints, saying Tavneos showed noninferiority of disease remission at 26 weeks and ...

KRd as a potential standard-of-care regimen in this hard-to-treat population of high-risk, newly diagnosed multiple myeloma,” said Lisa B. Leypoldt, MD.

There was a lot of excitement when Tepezza became the first drug approved for the treatment of thyroid eye disease in January ...